SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI. | ClinicLens
Although recent large-scale randomized trials have demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors following acute myocardial infarction (AMI) are safe, the mechanisms underlying their potential cardioprotective effects remain poorly understood. The aim of thi
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.